Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.06)
# 2,863
Out of 5,182 analysts
44
Total ratings
45%
Success rate
-7.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $20 → $18 | $8.97 | +100.67% | 1 | Apr 1, 2026 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $12 → $7 | $0.80 | +772.49% | 5 | Apr 1, 2026 | |
| DMRA Damora Therapeutics | Initiates: Outperform | $46 | $25.82 | +78.16% | 1 | Mar 25, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $101 → $126 | $95.20 | +32.35% | 5 | Mar 4, 2026 | |
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $207.94 | +9.65% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $18.68 | +92.72% | 1 | Dec 15, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $45.04 | +115.36% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $25.51 | +56.80% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $35.09 | +85.24% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $799.65 | +13.80% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.85 | +170.27% | 1 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $15 → $6 | $3.13 | +91.69% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $21.18 | +702.64% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $4.59 | +335.73% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $259.00 | -20.46% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $4.04 | +444.55% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.54 | +294.48% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $75.27 | -20.29% | 1 | Oct 5, 2022 |
MeiraGTx Holdings
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $18
Current: $8.97
Upside: +100.67%
Jasper Therapeutics
Apr 1, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $0.80
Upside: +772.49%
Damora Therapeutics
Mar 25, 2026
Initiates: Outperform
Price Target: $46
Current: $25.82
Upside: +78.16%
Mirum Pharmaceuticals
Mar 4, 2026
Maintains: Outperform
Price Target: $101 → $126
Current: $95.20
Upside: +32.35%
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $207.94
Upside: +9.65%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $18.68
Upside: +92.72%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $45.04
Upside: +115.36%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $25.51
Upside: +56.80%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $35.09
Upside: +85.24%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $799.65
Upside: +13.80%
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.85
Upside: +170.27%
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $3.13
Upside: +91.69%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $21.18
Upside: +702.64%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.59
Upside: +335.73%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $259.00
Upside: -20.46%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $4.04
Upside: +444.55%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.54
Upside: +294.48%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $75.27
Upside: -20.29%